The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.
The European Health Centre Innovation will now distribute SelectMDx and ConfirmMDx to its urology customers throughout the country.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
With the inclusion of ConfirmMDx in the Medi-Cal program, MDxHealth will seek access for the test in other state Medicaid programs.
The urine-based test is designed to identify men at high risk for aggressive prostate cancer, as well as those at low risk for the disease.
In the second half of the year, the firm plans to introduce a urine-based bladder cancer test and achieve sales growth between 30 and 50 percent.
MDxHealth said the positive medical policy decision adds to growing recognition of the ConfirmMDx test's value for improving patient outcomes.
In Science this week: genetic analysis of pollutant-tolerant fish, and more.
Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.
New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.
NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.